DoW Peer Reviewed Medical, Technology/Therapeutic Development Award
Funds product-oriented translation of established preclinical medical findings into regulatory-ready drugs, devices, tools, or practice products for PRMRP topic areas benefiting Service Members, Veterans, and Families.
⚑ Product-driven translational award; expects an established proof-of-concept or prototype to move through final preclinical development. · Outcome should be regulatory filing or translation into clinical practice, as applicable. · Topic must fit a congressionally directed FY26 PRMRP topic area and FY26 PRMRP strategic goal. · Up to 4 years; approximately $5.6M total cost cap per award; funded with FY26 funds with extended availability but awards made no later than 2027-09-30.
Unit fits — one characterization, each unit's own rules
| Tom Love Innovation Hub | 60 good | funds commercialization; prototyping/demonstration stage; deep-tech content |
| Physical Sciences & Engineering (demo) | 50 partial | technical depth: substantial; funds commercialization (capped) |
| IPPRA | 35 weak | peripheral portfolio topic: public_health; social/behavioral work is minor; funds commercialization — not a research fit; biomedical core — IPPRA health lane is communication/crisis/policy (capped) |
Description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award, a product-driven award mechanism, intends to support the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision-making tools or practice guidelines. Products in development should address or have dual purpose potential for the health care needs of military Service Members, Veterans and their Families.
Distinctive Features: For the PRMRP Technology/Therapeutic Development Award, the program expects the research proposed will take an already established proof-of-concept or prototype through the final stages of preclinical development. The PRMRP also expects that the research outcome will be a regulatory filing or translation of findings into clinical practice, as applicable.
Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $67.2M to fund approximately 12 Technology/Therapeutic Development Award applications with total cost caps of $5.6M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Apply
View on Grants.gov → CONTACT: Christopher L Baker Grants Officer <help@eBRAP.org>
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · Department of Defense (BAA-style) conventions SEE A DOD EXAMPLE →
Funder-faithful document skeletons — Department of Defense (BAA-style)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.